Certara stock edges lower as market watches valuation and analyst views

Published on 09/17/2026 at 20:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Certara stock is around USD 7.9 as of September 17, 2026, implying a market capitalization near USD 1.24 billion. Recent analyst and AI-based assessments highlight the stock’s health information services profile and potential upside scenarios.

CERT, US1567671046, Illustration mit AI erstellt.

Certara, Inc. (ISIN US1567671046) stock is trading around USD 7.9 as of September 17, 2026, which translates into a market capitalization of roughly USD 1.24 billion based on recent portal data. According to AI-driven overviews on financial forecasting platforms referencing Certara on September 17, 2026, the company is classified within health information services and analyzed alongside peers with similar data-driven business models.

Valuation snapshot and recent trading levels

In current league tables and multi-stock dashboards dated September 17, 2026, Certara stock is shown with a price region close to USD 7.9 per share and a market capitalization of about USD 1.24 billion, situating the company in the mid-cap segment of the United States healthcare technology space. One AI-based stock ranking tool lists Certara with this approximate market value while indicating that its evaluation relies on historical prices rather than live intraday quotes, underlining that investors should interpret the latest level as a snapshot of the broader valuation context rather than a highly volatile trading print.

For context, other portals that aggregate market data and forecasts show Certara’s market capitalization figure of USD 1.24 billion alongside an indication that the shares are monitored in combination with other health information services names. The combination of a single-digit share price and billion-dollar equity value points to a share count in the hundreds of millions and provides a starting point for investors considering earnings multiples and revenue-based valuation metrics.

Fundamental backdrop and recent results

While the most recent detailed quarterly and annual figures of Certara lie outside the immediate week-filtered search frame, they still define the fundamental narrative. Historically, the company has reported revenue in the hundreds of millions of dollars per year and has positioned itself as a provider of model-informed drug development and regulatory solutions, serving pharmaceutical companies and regulators with software and services that help optimize clinical trial design and submissions. These historical revenue levels, combined with the current market capitalization around USD 1.24 billion as of September 17, 2026, suggest that the market is applying a revenue multiple typical for niche healthcare technology platforms with recurring software and consulting income.

Investors often compare such market capitalization and price figures with prior-year fundamentals to gauge whether the stock is pricing in growth or compression. If historical revenue stood, for example, at roughly USD 380 million in a recent fiscal year, a USD 1.24 billion market capitalization would imply a price-to-sales ratio a little above 3 times, which is moderate for specialized health information services businesses. The exact ratio naturally shifts with each earnings report, but the comparison illustrates how current valuation levels relate to the company’s established revenue base.

Analyst and AI-based perspectives

Beyond classical equity analysts, Certara stock appears in AI-based forecasting tools that screen thousands of stocks per day. In one such overview dated September 17, 2026, Certara (ticker CERT) is listed with an AI signal and a market capitalization of USD 1.24 billion, and the provider comments that its system reaches a Spearman correlation of about negative 10 percent with historical data and an average accuracy above 67 percent across over 4,000 stocks analyzed daily. While these statistics describe the model rather than Certara specifically, they illustrate the growing use of algorithmic evaluation in assessing mid-cap healthcare technology companies like Certara.

For investors, these AI and consensus tools are most useful when combined with conventional research. A market capitalization of around USD 1.24 billion as of September 17, 2026 provides a concrete anchor for such assessments, and the fact that Certara is grouped in health information services indicates that its valuation is often compared with other data-heavy healthcare names rather than with pure biopharmaceutical issuers. The price level in the high single digits means that even small absolute moves can translate into noticeable percentage changes, an important consideration for risk management.

Stock level and investor perspective

With Certara stock trading near USD 7.9 on its US exchange as of September 17, 2026 and the equity value around USD 1.24 billion, the shares currently reflect a mid-cap valuation profile in health information services. For investors, the next major catalyst will likely be the company’s upcoming earnings report or a new guidance update, which could recalibrate revenue and margin expectations and, in turn, the valuation multiple applied to the stock.